Join Kyle George, PA-C, a rheumatology physician assistant in Idaho, as he reviews the dosing recommendations for Upadacitinib (Rinvoq) across rheumatology, gastroenterology, and dermatology.

Upadacitinib is a selective JAK1 inhibitor used for a range of immune-mediated diseases. In adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA), the recommended dose is 15 mg once daily in an extended-release tablet formulation.

For pediatric patients with juvenile idiopathic arthritis (JIA) and PsA, dosing is weight-based using a 1 mg/mL solution:

10-20 kg: 3 mg twice daily

20-30 kg: 4 mg twice daily

≥30 kg: 6 mg twice daily or 15 mg once daily (extended-release tablet)

Higher doses of Upadacitinib are used in gastroenterology and dermatology, particularly for conditions such as Crohn’s disease, ulcerative colitis, and atopic dermatitis, where increased inhibition of inflammatory pathways is required.

Understanding proper dosing is essential for optimizing treatment efficacy while minimizing risks across different patient populations.

For more information on Upadacitinib and its clinical applications, visit the RhAPP website and download the RhAPP ACE App.